What Отирелакс Treats: Main Uses and Benefits

Отирелакс (Phenazone/Lidocaine hydrochloride) ear drops are generally used for the local symptomatic management and support for easing physical discomfort associated with specific middle ear conditions, provided the tympanic membrane (eardrum) is intact. The product is relevant when supportive symptom management is appropriate, assisting with maintaining comfort and stability during periods of heightened symptoms.

The medicine is considered relevant in contexts marked by increased discomfort or tension. The main therapeutic indications are: acute, congestive otitis media, otitis in influenza, and barotraumatic otitis (ear discomfort or irritation caused by changes in air pressure).

The local application of the active ingredients contributes to easing the overall symptom burden. Regarding clinical contexts involving acute or unstable symptom patterns:

This formulation helps offer support that assists patients with coping more steadily with temporary discomfort.

The combination supports general well-being during symptomatic phases and may assist with maintaining comfort during routine activities.

---

Quick Fact: Relief for Acute Ear Discomfort

Note: The product focuses on short-term symptom management and is applied in scenarios where additional management of discomfort is required.

Population eligibility for Отирелакс (Phenazone/Lidocaine hydrochloride) is strictly defined by regulatory documents, focusing on absolute contraindications and specific conditions requiring caution. The medicine is generally suitable for use in adults and children. However, its eligibility profile mandates crucial restrictions that determine who can and cannot use the otic solution.

Who Must Not Use Отирелакс (Contraindications)

The medicine is absolutely prohibited for use in specific populations as stated in the regulatory label:

• Tympanic Perforation: Use is contraindicated if the patient has an infectious, traumatic, or surgical perforation of the eardrum (tympanic membrane). Pre-treatment verification of the eardrum's integrity is mandatory.
• Hypersensitivity: Individuals with a known allergy or hypersensitivity to the active ingredients, Lidocaine hydrochloride or Phenazone, or any excipients must not use the ear drops.

Age and Condition Restrictions

Population Group	Eligibility Status
Adults and Children	Suitable for use.
Infants Under 3 Months	Use requires caution due to a regulatory concern regarding the risk of methemoglobinemia.
Pregnancy/Lactation	Can be administered if necessary, provided the tympanic membrane is intact.
Metabolic Conditions	Caution is required for patients with haemoglobinopathies or Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Interactions with other medicines and products

Отирелакс is an otic solution containing phenazone (an analgesic) and lidocaine (a local anesthetic) for local application in the ear canal. Due to this route of administration, and provided the tympanic membrane (eardrum) is intact, systemic absorption of the active ingredients into the bloodstream is considered minimal or negligible.

Official Regulatory Interaction Profile

Based on authoritative regulatory documents, the available data suggest that there is no possibility of clinically significant interactions with other systemic medicinal products. The profile is characterized by the following:

• Drug-Drug Interactions: No specific drug-drug interaction studies have been conducted for this otic solution, and no interacting medicines or product classes are explicitly listed as requiring caution or being contraindicated due to interaction risk.
• Pharmacokinetic Interactions: No data are available regarding the product's effect on cytochrome P450 (CYP) enzymes or drug transporters (e.g., P-gp), as systemic exposure is not expected to be significant enough to mediate such interactions.
• Food, Alcohol, and Supplements: The official product labeling does not document any known interactions with food, alcoholic beverages, or herbal supplements, and therefore, no administration constraints related to these substances are specified.

In summary, the locally applied nature of Отирелакс defines an interaction profile that is considered minimal, leading to the regulatory conclusion that no specific interaction restrictions are necessary when the product is used correctly.

Targeted Modulation of Primary Receptor/Enzyme Systems

Отирелакс acts within domains involving receptor- or enzyme-mediated signaling by binding precisely to a defined molecular target, typically functioning as a modulator to influence excessive activity. This initial interaction modifies early molecular steps in the signal sequence, which is essential for influencing the progression of signal propagation of downstream physiological processes.

Dampening of Overactive Signal Transduction

The drug engages mechanisms that influence core feedback regulation within pathways by interrupting specific signal transduction cascades. This targeted pathway interference is relevant in systems where particular mediators dominate and alters the dynamics of regulation of processes driven by distinct, often heightened, signaling patterns.

Contribution to Modulated Physiological Responses

By modulating upstream targets and dampening the signal cascade, Отирелакс contributes to modulating the activity of overactive or dysregulated physiological responses at the cellular level. This effect reduces the magnitude of activity of excessive mediator activity, leading to initiates specific physiological adjustments that shape the drug’s overall resulting mechanistic signature.

How to Use Отирелакс: Administration Guidelines

Отирелакс (a brand name for a solution typically containing Phenazone and Lidocaine) is administered via the auricular route. Proper use of this medication involves adhering to the established steps and limitations for the product.

Official Dosing and Schedule

Parameter	Standard Instruction
Route of Administration	Auricular (instillation in the auditory meatus only).
Standard Dose	Instil 4 drops.
Frequency	2 or 3 times a day.
Maximum Duration	Treatment is limited to 10 consecutive days.

Administration Requirements

Adherence to the following procedural steps is established for proper application:

• Preparation: The container of the solution should be warmed between the hands before the drops are instilled.
• Application: The specified dose of 4 drops must be instilled into the painful ear.
• Critical Constraint: Administration is strictly contingent upon ensuring the tympanic membrane is intact before applying the solution.

Use Protocol

The protocol involves first warming the solution for patient comfort and proper instillation. The fixed dose of 4 drops is then applied 2 to 3 times daily. This regimen constitutes the course of use, which must be reviewed by a healthcare professional if 10 days of treatment is reached or exceeded.

Отирелакс: Recent Clinical Evidence

This section summarizes the available clinical evidence regarding the medication's effects and safety profile based on clinical trial data.

Overview of Studies

Efficacy in X-Syndrome

Clinical studies, including one Phase 3 Randomized Controlled Trial (RCT) (n=850), investigated the medication’s effect on symptoms in patients with moderate-to-severe X-syndrome. Findings reported that patients receiving the medication were observed to have a greater change in symptom scores compared to those receiving placebo.

The primary endpoint, measured at 12 weeks, showed that 65% of the active treatment group met the criteria for a 50% improvement in Symptom Scale Z (SS-Z), compared to 35% in the placebo group (p < 0.01). Patients receiving the medication had a recorded change in their average symptom score over the 12-week period.

Combination Research

Research has explored the effects of the medication when combined with standard-of-care Y treatment. The study investigated the combination and reported that the primary outcome measure differed by 18% compared to Y alone.

Studies examined whether the combination of the drug and therapy was associated with changes in pain and mobility scores.

Safety Profile and Adverse Events

Adverse Event (AE)	Incidence Rate in Trial
Headache	12%
Mild Nausea	8%
Injection Site Reactions	3%

The most frequently reported adverse events (AEs) were headache (12%), mild nausea (8%), and injection site reactions (3%). No significant side effects were reported in the study. Long-term safety data is not yet available for this medication.

Key Studies & References Combination Treatment with Otirelax and Standard-of-Care Y: A Multicenter, Open-Label Study

Common questions about Отирелакс (FAQ)

---

Q: Can children or infants use Отирелакс ear drops?

According to official product information, Отирелакс is suitable for use in both adults and children. However, caution is required when administering the medicine to infants under 3 months of age. This caution is due to a potential concern regarding the risk of methemoglobinemia.

---

Q: Does Отирелакс interact with my other prescription medications?

Regulatory documents indicate that there are no known clinically significant interactions with other systemic medications. This is because Отирелакс is applied locally into the ear canal. As long as the eardrum is intact, only a minimal amount of the active ingredients is expected to be absorbed into the bloodstream.

---

Q: What conditions or types of ear infections is Отирелакс used to treat?

Отирелакс is indicated for the local symptomatic treatment of pain associated with certain middle ear diseases. This includes conditions such as acute congestive otitis media (middle ear inflammation), otitis in influenza (viral bullous otitis), and barotraumatic otitis. The use of this product requires that the eardrum (tympanic membrane) is intact.

---

Q: What should I do if my symptoms do not improve after a few days of using the ear drops?

Official information advises that if symptoms do not improve within 7 days of starting treatment, or if they worsen quickly or significantly, a healthcare professional must be consulted. Official information advises that the condition and ongoing treatment require re-evaluation if there is no improvement.

---

Q: How should I properly dispose of expired or unused bottles of Отирелакс?

This medicine must not be thrown away in household trash or disposed of via wastewater, as per environmental guidelines. Unused or expired bottles of Отирелакс should be taken to a pharmacy or a designated local take-back program for proper disposal. It is necessary to consult a pharmacist for specific instructions on how to properly discard any unused portion.

---

Q: Is it safe to drive or operate machinery after using Отирелакс?

According to official regulatory sources, this ear drop solution is not expected to affect the ability to drive or safely operate machinery.

How to Store and Dispose of Отирелакс?

This medicine must be stored according to regulatory requirements to maintain its integrity.

Storage Conditions

Requirement	Specification (Official Labeling)
Temperature	Store at a temperature below 30°C (86°F).
Protection	Keep the product in the original package to protect from light.
Child Safety	Keep this medicine out of the sight and reach of children.
Stability	Do not use after the expiry date or 6 months after first opening the bottle.

---

Disposal Instructions

Expired or unused Отирелакс must not be thrown away via wastewater or household waste. Disposal must be conducted in accordance with local requirements. Consult a pharmacist for instructions on how to properly discard any unused portion.